Oncotype DX testing a winner for guiding breast cancer therapy

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.645, 2012-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NICE recommends Oncotype DX to guide breast cancer therapy . . .

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 672, 2013-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

OncotypeDX-guided treatment of breast cancer cost effective

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 529, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Keeping abreast of Oncotype DX testing

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 651, 2012-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

By Bartlett John M.S.

American Journal of PharmacoGenomics, Vol. 5, Iss. 5, 2005-01 ,pp. : 303-315

Adis International

Access to resources Recommend Favorite

Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: Some concerns

By Lagios Michael D. Silverstein Melvin J.

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1085-1085

Blackwell Publishing

Access to resources Recommend Favorite